Yahoo · Sep 25, 2026
Scholar Rock Poised for De-risked Commercial Ramp in Neuromuscular Space, Wedbush Says
Scholar Rock (SRRK) is well positioned for a durable, de-risked commercial ramp in the neuromuscular
SR
NASDAQ · SRRK
Scholar Rock Holding Corporation
Healthcare · Biotechnology
$46.81
Down-$3.41 (-7.28%)
Updated Oct 5, 2026, 11:51 PM
SID Score
4.7/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 4.78B
- P/E ratio
- -15.08
- Dividend yield
- 0.00%
- 52-week range
- $27.07 – $61.76
- Volume
- 1.24M
- Avg. volume
- 2.6M
Price performance · SRRK
SRRK price history
1M range · 19 trading sessions · Daily adjusted prices
Prices through Oct 2, 2026
SRRK closed at $46.81 after 19 trading sessions, down 18.48% for the selected period.
- Last close
- $46.81
- Period change
- -18.48%
- Period low
- $46.16
- Period high
- $57.42
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 2, 2026 | $46.74 | $47.80 | $46.08 | $46.81 | 1.24M |
| Oct 1, 2026 | $48.32 | $48.82 | $46.07 | $46.16 | 1.06M |
| Sep 30, 2026 | $48.42 | $49.605 | $48.11 | $48.32 | 1.29M |
| Sep 29, 2026 | $48.98 | $49.35 | $47.47 | $47.75 | 1.07M |
| Sep 28, 2026 | $48.10 | $49.98 | $47.76 | $49.13 | 1.57M |
| Sep 25, 2026 | $49.19 | $49.46 | $48.185 | $48.63 | 1.88M |
| Sep 24, 2026 | $50.08 | $50.405 | $48.21 | $48.61 | 2.03M |
| Sep 23, 2026 | $51.19 | $51.735 | $49.25 | $49.85 | 2.49M |
| Sep 22, 2026 | $48.07 | $51.675 | $48.07 | $51.19 | 3.75M |
| Sep 21, 2026 | $47.35 | $49.15 | $46.54 | $48.16 | 2.9M |
| Sep 18, 2026 | $48.02 | $48.525 | $45.875 | $46.65 | 3.25M |
| Sep 17, 2026 | $49.52 | $49.95 | $48.00 | $49.02 | 3.49M |
| Sep 16, 2026 | $50.01 | $50.65 | $48.59 | $49.37 | 3.66M |
| Sep 15, 2026 | $50.775 | $51.1067 | $46.54 | $50.00 | 5.25M |
| Sep 14, 2026 | $56.505 | $56.90 | $51.58 | $51.85 | 4.05M |
| Sep 11, 2026 | $55.67 | $56.935 | $54.91 | $55.41 | 994.4K |
| Sep 10, 2026 | $54.01 | $56.71 | $53.86 | $55.67 | 1.18M |
| Sep 9, 2026 | $57.30 | $57.65 | $54.44 | $54.62 | 1.6M |
| Sep 8, 2026 | $54.088 | $57.79 | $54.00 | $57.42 | 1.84M |
Latest SRRK news
The latest Smart Investors Daily articles mentioning SRRK.
Stock researchCompany · Overview
Company
Market Activity
Research & News
SRRK research
Overview
Company profile and research snapshot.
Company profile
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $49.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 24, 2026 | Truist Securities | Buy | — |
| Sep 21, 2026 | JP Morgan | Overweight | — |
| Sep 15, 2026 | Wedbush | Outperform | — |
| Sep 15, 2026 | Barclays | Equal-Weight | — |
| Sep 15, 2026 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Sep 24, 2026
Truist Securities Maintains Buy on Scholar Rock Holding, Raises Price Target to $77
Truist Securities analyst Srikripa Devarakonda maintains Scholar Rock Holding (NASDAQ:SRRK) with a Buy and raises the price target from $76 to $77.
Yahoo · Sep 21, 2026
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., September 21, 2026--Scholar Rock (NASDAQ: SRRK; the "Company") today announced that the company granted inducement equity awards covering an aggregate of 83,102 shares of its common stock to ten newly hired employees, consisting of inducement stock options to purchase an aggregate of 23,801 shares of common stock and inducement restricted stock units, covering an aggregate of 59,301 shares of its common stock.
Benzinga · Sep 21, 2026
JP Morgan Maintains Overweight on Scholar Rock Holding, Raises Price Target to $70
JP Morgan analyst Tessa Romero maintains Scholar Rock Holding (NASDAQ:SRRK) with a Overweight and raises the price target from $63 to $70.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
